Summary
Boston Scientific Corporation's 2009 10-K filing paints a picture of a company navigating a challenging economic environment while making strategic moves. The report highlights efforts to manage costs and streamline operations, crucial for maintaining profitability in a competitive medical device market. Investors should note the company's focus on innovation and product development, which are key drivers for future growth. While specific financial figures from the provided table of contents are limited, the structure of the report suggests a comprehensive review of the company's performance, risks, and strategic direction. The filing also underscores the importance of regulatory compliance and legal proceedings, which can significantly impact financial performance and investor confidence. The inclusion of various agreements and stipulations, such as a Plea Agreement and Corporate Integrity Agreement, indicates a proactive approach to addressing past issues. Investors will want to pay close attention to the Management's Discussion and Analysis (MD&A) and the Financial Statements for a deeper understanding of the company's financial health and operational strategies.
Financial Highlights
47 data points| Revenue | $8.19B |
| Cost of Revenue | $2.58B |
| Gross Profit | $5.61B |
| SG&A Expenses | $2.63B |
| Operating Expenses | $6.51B |
| Operating Income | -$894.00M |
| Interest Expense | $407.00M |
| Net Income | -$1.02B |
| EPS (Basic) | $-0.68 |
| EPS (Diluted) | $-0.68 |
| Shares Outstanding (Basic) | 1.51B |
| Shares Outstanding (Diluted) | 1.51B |
Key Highlights
- 1The company is filing its annual report for the fiscal year ending December 30, 2009, providing a look back at its performance and strategic initiatives.
- 2The report structure indicates a detailed examination of the company's business, including its products, services, and market position.
- 3Significant emphasis is placed on Risk Factors, suggesting that management is aware of and actively addressing potential challenges.
- 4The filing includes discussions on legal proceedings and regulatory matters, such as a Plea Agreement and Corporate Integrity Agreement, pointing to ongoing compliance efforts.
- 5Investors can expect a thorough review of the company's financial condition and results of operations within the Management's Discussion and Analysis (MD&A) section.
- 6Details on equity, related stockholder matters, and issuer purchases of equity securities are presented, offering insights into shareholder value and capital management.
- 7The report provides selected financial data and full financial statements, which are critical for assessing the company's financial health.